0BABA.US Overview

Nomura's Analysis of Alibaba: Nomura's report indicates that the recent sell-off of Alibaba's stock was unjustified, attributing it to a weak quarterly performance without acknowledging improvements in the company's operations and AI initiatives.

Revised Financial Projections: The broker has lowered Alibaba's adjusted EBITA forecasts for FY26-27 by 5% and 14%, respectively, due to weaker earnings and increased investment in AI, but expects a 28% increase in consolidated EBITA by FY27.

Revenue Growth: Alibaba's revenue for 3QFY26 increased by 1.7% YoY to RMB284.8 billion, falling 2% short of market expectations.

EBITA Decline: The company's adjusted EBITA dropped by 57% YoY to RMB23.4 billion, which was below the anticipated RMB31.4 billion.

Cloud Business Performance: Alibaba's cloud segment saw a significant revenue growth of 36%, surpassing market expectations by 2 percentage points.

Target Price Adjustment: CMBI has slightly reduced its target price for Alibaba from USD206.4 to USD203.7 while maintaining a Buy rating.

JP Morgan's Analysis of Alibaba: JP Morgan's report indicates that Alibaba's stock is undervalued, primarily reflecting only its domestic e-commerce earnings, while overlooking the potential of Alibaba Cloud and quick commerce platforms.

Forecast Adjustments: The broker has lowered its revenue and adjusted EPS forecasts for Alibaba for FY26 and FY27, resulting in a reduction of the target stock price for both US and H-share listings.

Alibaba Cloud Growth: Alibaba Cloud has shown significant revenue growth, rebounding to 36% in the latest quarter, with AI product revenue experiencing triple-digit growth for ten consecutive quarters.

Jefferies' Position: Jefferies has also adjusted its target price for Alibaba to $206 while maintaining a Buy rating, citing improvements in quick commerce fundamentals.

AI Stack Advantage: Morgan Stanley's report highlights that possessing a full AI stack significantly increases the chances of success in the AI sector, with self-developed chips reducing competition and regulatory risks.

Alibaba's Position: The broker upgraded Alibaba to its top pick, citing its strong AI capabilities, including top-tier self-developed chips and being a leading cloud infrastructure provider, positioning it as a global AI winner.

Tencent's Potential: Although Tencent is currently lagging behind, it benefits from the WeChat ecosystem, which may allow it to catch up quickly in the AI space.

Baidu's Challenges: Baidu faces higher risks of AI disruption in its core search business, despite having local chip competitor Kunlunxin in the market.

AI Ads Spending Growth: AI applications are significantly driving ad spending growth in China, with expectations of reaching tens of billions of RMB this year, reflecting a year-on-year increase of 60-70%.

Market Competition: Major players like ByteDance and Tencent are leading the ad revenue growth due to their scale and efficiency, while Baidu and Kuaishou face challenges in inventory and conversion.

Brand Advertising Focus: Weibo and Focus Media primarily concentrate on brand advertising, with Focus Media having a unique position in offline ads through its partnership with Alibaba.

Short Selling Insights: The report includes data on short selling for various companies, indicating market sentiments and potential risks associated with their stock performance.

BABA-W Stock Performance: BABA-W (09988.HK) experienced a decline of 1.173%, with short selling amounting to $1.56 billion and a ratio of 13.872%.

Stake Reduction in RS MACALLINE: BABA (BABA.US) reduced its stake in RS MACALLINE (01528.HK) by 3.4407 million shares, lowering its holding from 6.03% to 5.93% at an average price of RMB2.6334.

Market Insights from UBS: UBS suggests that if China successfully achieves reflation, the stock market could potentially rise by 20%, advising a reduction in exposure to the internet sector.

Stock Quote Delays: It is noted that Hong Kong stock quotes are delayed by at least 15 minutes, and real-time streaming for US stocks is also subject to delays for OTC quotes.